# Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

> **NCT00322036** · PHASE3 · TERMINATED · sponsor: **Myrexis Inc.** · enrollment: 800 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia

## Interventions

- **DRUG:** MPC-7869
- **DRUG:** MPC-7869

## Key facts

- **NCT ID:** NCT00322036
- **Lead sponsor:** Myrexis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 800 (ACTUAL)
- **Why stopped:** Myriad has discontinued the development of Flurizan.
- **Last updated:** 2008-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322036, "Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00322036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*